Biktarvy And Lenacapavir Launches Will Drive Cautious Future Progress
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 26 Analysts
Published
09 Apr 25
Updated
30 Jul 25
AnalystLowTarget's Fair Value
US$91.83
20.1% overvalued intrinsic discount30 Jul
US$110.28
1Y
49.0%7D
-3.9%